Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis
Issued Date
2022-12-01
Resource Type
ISSN
14659921
eISSN
1465993X
Scopus ID
2-s2.0-85132276294
Pubmed ID
35729565
Journal Title
Respiratory Research
Volume
23
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Respiratory Research Vol.23 No.1 (2022)
Suggested Citation
Zhao Y., Gao Y., Petnak T., Cheungpasitporn W., Thongprayoon C., Zhang X., Moua T. Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis. Respiratory Research Vol.23 No.1 (2022). doi:10.1186/s12931-022-02082-x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85297
Title
Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis
Other Contributor(s)
Abstract
Background: Rituximab (RTX) has been previously reported as directed treatment in patients with connective-tissue disease-related interstitial lung diseases (CTD-ILD). A systematic assessment of treatment effect size on pulmonary function outcomes and related adverse effects in patients with CTD-ILD has not been previously reported. Methods: We performed a systematic review and meta-analysis of published reports from PubMed, Embase, and Cochrane Libraries. Randomized and non-randomized controlled trials, case–control, cohort, and case series (with five or more cases) containing individual pulmonary function data and adverse effects were included. Study endpoints were pre- and post-treatment change in percent predicted forced vital capacity (FVC %) and diffusion capacity for carbon monoxide (DLCO%), along with reported drug-related adverse events. Results: Twenty studies totaling 411 patients were identified with 14 included in the meta-analysis of pulmonary function and six in the descriptive review. Random effects meta-analysis of pre- and post-treatment pulmonary function findings demonstrated increases in FVC% (n = 296) (mean difference (MD) 4.57%, [95% CI 2.63–6.51]) and DLCO% (n = 246) (MD 5.0% [95% CI 2.71–7.29]) after RTX treatment. RTX treatment-related adverse effects were reported in 13.6% of the pooled cohort. Conclusions: A systematic assessment of post-treatment effect size suggests a potential role for RTX in stabilizing or improving lung function in patients with CTD-ILD, with a modest but not insignificant adverse effect profile.